Drugs / SAR442085
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04000282 | Aug 2019 → Aug 2022 | plasma cell myeloma | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR442085 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04000282 ↗ |
| Modality | Monoclonal antibody | “a novel fragment crystallisable (Fc)-modified anti-CD38 monoclonal antibody (mAb)” PMID 38993150 ↗ Jul 2024 |
| Route | Intravenous | “Route of administration: intravenous” NCT04000282 ↗ |
| Target | CD38 | “anti-CD38 monoclonal antibody” PMID 38993150 ↗ Jul 2024 |